Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.
Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.
Astrazeneca also said that for the secondary endpoint of overall survival, a "strong trend" was seen in the interim analysis that favors the Imfinzi-based regimen.
The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.